Clinical Trial Update: Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy of cis-urocanic acid at 2.5% and 5% in moderate to severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Cis-urocanic acid (cis-urocanic acid)

Snippet

Sponsor: BioCis Pharma Ltd | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED